AR033873A1 - Mutantes de virus de la rabia atenuado recombinantes y vacunas vivas - Google Patents

Mutantes de virus de la rabia atenuado recombinantes y vacunas vivas

Info

Publication number
AR033873A1
AR033873A1 ARP020101463A ARP020101463A AR033873A1 AR 033873 A1 AR033873 A1 AR 033873A1 AR P020101463 A ARP020101463 A AR P020101463A AR P020101463 A ARP020101463 A AR P020101463A AR 033873 A1 AR033873 A1 AR 033873A1
Authority
AR
Argentina
Prior art keywords
mutants
mutation
residues
codon
arg
Prior art date
Application number
ARP020101463A
Other languages
English (en)
Inventor
Teshome Mebatsion
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of AR033873A1 publication Critical patent/AR033873A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Mutantes de RV recombinantes que comprenden una mutación combinada en dos partes diferentes del genoma viral, que involucra los genes P y G. Las mutaciones en el gen P abarcan preferentemente los residuos 139 a 170, mejor los residuos 139 a 149, mejor aun los residuos 143-149. La mutación puede ser una sustitución o deleción de uno o más aminoácidos en la región mencionada, como así también combinaciones de deleción y sustitución. Los mutantes preferidos según la presente pueden obtenerse eliminando los residuos 143 a 149 o 139 a 149 de la fosfoproteína (P) del virus de la rabia y reemplazando simultáneamente Arg en la posición 333 de la glicoproteína en otro residuo, preferentemente Asp en lugar de Arg. Sorprendentemente, cuando se introdujeron estas mutaciones en virus de rabia carentes de Arg en la posición 333 de su proteína G, se observó una reducción drástica en la patogenicidad de ratones lactantes. Este descubrimiento inesperado tiene una profunda ventaja en el desarrollo de vacunas contra la rabia atenuadas vivas más seguras. La mutación en el gen G puede comprender una mutación del codón Arg333 en un codón que difiera en uno, dos o tres nucleótidos de dicho codón Arg333. Preferentemente los mutantes son mutantes de una cepa de RV en la que se sustituyen los tres nucleótidos del codón Arg333.
ARP020101463A 2001-04-23 2002-04-23 Mutantes de virus de la rabia atenuado recombinantes y vacunas vivas AR033873A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01201464 2001-04-23
EP01203773 2001-10-05

Publications (1)

Publication Number Publication Date
AR033873A1 true AR033873A1 (es) 2004-01-07

Family

ID=26076884

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101463A AR033873A1 (es) 2001-04-23 2002-04-23 Mutantes de virus de la rabia atenuado recombinantes y vacunas vivas

Country Status (10)

Country Link
US (1) US6887479B2 (es)
EP (1) EP1253197B1 (es)
AR (1) AR033873A1 (es)
AT (1) ATE316572T1 (es)
BR (1) BR0201366A (es)
CA (1) CA2382993A1 (es)
DE (1) DE60208854T2 (es)
ES (1) ES2257505T3 (es)
PT (1) PT1253197E (es)
TR (1) TR200201081A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007000445A (es) * 2004-07-12 2007-04-16 Univ Jefferson Composiciones de virus de rabia recombinantes-.
AU2006304268B2 (en) 2005-10-14 2011-09-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus vector systems and compositions and methods thereof
US20100278864A1 (en) * 2005-12-14 2010-11-04 University Of Georgia Research Foundation, Inc. Rabies Vaccine
FR2944292B1 (fr) 2009-04-08 2013-08-23 Sanofi Pasteur Procede de purification du virus rabique
CN103068985A (zh) * 2010-06-24 2013-04-24 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) 抗狂犬病的广谱狂犬病病毒属病毒疫苗
ES2528472T3 (es) 2011-02-03 2015-02-10 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Vacunas multivalentes para el virus de la rabia y filovirus
EP4104854A3 (en) 2016-04-04 2023-03-08 The United States of America as represented by the Secretary of the Department of Health and Human Services Multivalent vaccines for rabies virus and coronaviruses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6719981B1 (en) * 1998-11-27 2004-04-13 Akzo Nobel N.V. Stable, attenuated rabies virus mutants and live vaccines thereof

Also Published As

Publication number Publication date
TR200201081A3 (tr) 2002-11-21
DE60208854D1 (de) 2006-04-13
EP1253197B1 (en) 2006-01-25
EP1253197A1 (en) 2002-10-30
TR200201081A2 (tr) 2002-11-21
ES2257505T3 (es) 2006-08-01
US20020164356A1 (en) 2002-11-07
ATE316572T1 (de) 2006-02-15
DE60208854T2 (de) 2006-08-17
PT1253197E (pt) 2006-06-30
US6887479B2 (en) 2005-05-03
BR0201366A (pt) 2003-06-10
CA2382993A1 (en) 2002-10-23

Similar Documents

Publication Publication Date Title
DK1098961T3 (da) Gensplejsede svækkede vira, der inducerer interferon
JP2021182922A5 (es)
JP2009544333A5 (es)
JP2017522907A5 (es)
ES2150416T3 (es) Vacuna virica defectiva producida por una linea celular complementada en trans.
ES2140418T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
RU2012107671A (ru) Композиция для лечения инфекции вирусом гепатита в
JP2009540801A5 (es)
AR033873A1 (es) Mutantes de virus de la rabia atenuado recombinantes y vacunas vivas
AU2017353868C1 (en) Synthetic chimeric poxviruses
JP2020188776A (ja) 組換えオルフウイルスベクター
MXPA04010683A (es) Proteina de fusion de las proteinas reguladoras/accesorias del vih.
SA520420568B1 (ar) جين متماثل من الديسموتاز فائق الأكسيد المستقر واستخداماته (sod)
US11534417B2 (en) Enhanced expression of RNA vectors
ES2606605T3 (es) Vacuna para el BVDV
AR124736A1 (es) EFECTO SINÉRGICO DE SMN1 Y miR-23a EN EL TRATAMIENTO DE LA ATROFIA MUSCULAR ESPINAL
EP3158060B1 (en) Method for rapid generation of an infectious rna virus
AR126396A1 (es) VARIANTES DESOPTIMIZADAS DE SARS-CoV-2 Y MÉTODOS Y USOS DE LAS MISMAS
Qian et al. Pathogenicity and stability of a truncated DNAβ associated with Tomato yellow leaf curl China virus
Zhou et al. Chimeric Flock House virus protein A with endoplasmic reticulum-targeting domain enhances viral replication and virus-like particle trans-encapsidation in plants
US11154607B2 (en) Genetically attenuated nucleic acid vaccine
CL2023001650A1 (es) Tratamiento de la enfermedad de danon
AR021406A1 (es) Un mutante del virus de la rabia recombinante, y una vacuna antirrabica con virus vivos atenuados
AR052743A1 (es) Vector plasmidico de transferencia y virus canarypox recombinante
MX2023001137A (es) Beta-glucocerebrosidasa mutada con estabilidad mejorada.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee